Goldman Sachs
ASBP

Goldman Sachs’s Aspire Biopharma ASBP Stock Holding History

Goldman Sachs’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16
Closed -$5.03K – 6749
2025
Q2 		$5.03K Buy
+16
New +$7.59K ﹤0.01% 6020
2023
Q2 		– Sell
-377
Closed -$4.75M – 6136
2023
Q1 		$4.75M Hold
377
– – ﹤0.01% 3114
2022
Q4 		$4.67M Hold
377
– – ﹤0.01% 3234
2022
Q3 		$4.59M Buy
+377
New +$4.55M ﹤0.01% 3202

Other funds holding ASBP

CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
PA
Procyon Advisors Shelton, Connecticut $2.32B AUM 26.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OAS
Optivise Advisory Services Franklin, Tennessee $197M AUM 26.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
VAS
VR Advisory Services Camana Bay, Grand Cayman, Cayman Islands $845M AUM 22.79% 1-Year Est. Return
RA
Resolute Advisors San Francisco, California $242M AUM 52.95% 1-Year Est. Return
TSW
Three Seasons Wealth Salt Lake City, Utah $262M AUM 45.03% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return

Goldman Sachs's ASBP Position: Q3 2025 in Review

Goldman Sachs sold out of Aspire Biopharma (ASBP) in Q3 2025, closing a stake of 16 shares — an estimated $5.03K sold.

Goldman Sachs first reported a position in ASBP in Q3 2022 and held it in 4 quarters. The position peaked at $4.75M in Q1 2023. 23 funds tracked by Wall St. Rank hold ASBP as of Q3 2025.

  • Goldman Sachs reported no remaining Aspire Biopharma position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 16 Aspire Biopharma shares in Q3 2025, an estimated $5.03K.
  • Goldman Sachs first reported a position in Aspire Biopharma in Q3 2022 and held it in 4 quarters.
  • Goldman Sachs's Aspire Biopharma position peaked at $4.75M in Q1 2023.
  • 23 funds tracked by Wall St. Rank held Aspire Biopharma as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.